• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Chung Dong Chune Christopher was granted 35,056 shares and returned $2,793,029 worth of shares to the company (83,374 units at $33.50), closing all direct ownership in the company (for tax liability)

    7/21/22 5:06:03 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NTUS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    CHUNG DONG CHUNE CHRISTOPHER

    (Last) (First) (Middle)
    C/O NATUS MEDICAL INCORPORATED
    3150 PLEASANT VIEW ROAD

    (Street)
    MIDDLETON WI 53562

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NATUS MEDICAL INC [ NTUS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/21/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.001 par value per share 07/21/2022 A 35,056(1) A $0 83,374 D
    Common Stock, $0.001 par value per share 07/21/2022 D 83,374(2) D $33.5(3) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Nonqualified Stock Option $20.68 07/21/2022 D 35,360 (4) 11/13/2030 Common Stock 35,360 $12.82 0 D
    Explanation of Responses:
    1. Represents the number of shares of Common Stock subject to performance-based stock unit awards that vested and were settled as a result of the merger ("Merger") pursuant to the previously announced Agreement and Plan of Merger, dated April 17, 2022, between Prince Parent Inc. ("Parent"), Prince Mergerco Inc, and Issuer ("Merger Agreement").
    2. Disposed of as a result of the Merger.
    3. Each share of Common Stock, including shares underlying equity awards, was cancelled pursuant to the Merger Agreement in exchange for the right to receive the cash consideration provided in the Merger Agreement, subject to applicable tax withholding.
    4. This option, which provided for vesting in four equal annual installments beginning November 13, 2021, was (to the extent not previously exercised) cancelled in the Merger pursuant to the Merger Agreement in exchange for a cash payment, per option share, representing the difference between the per share exercise price of the option and the per share cash consideration provided in the Merger Agreement ($33.50), subject to applicable tax withholding.
    Remarks:
    /s/ DOUGLAS BALOG by POWER OF ATTORNEY 07/21/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NTUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTUS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Schroeder Alice D. returned $750,601 worth of shares to the company (22,406 units at $33.50), closing all direct ownership in the company (for withholding tax)

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:25:24 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Moore Bryant M returned $338,819 worth of shares to the company (10,114 units at $33.50), closing all direct ownership in the company (withholding obligation)

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:22:51 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: Levine Joshua returned $1,252,464 worth of shares to the company (37,387 units at $33.50), closing all direct ownership in the company to cover taxes

    4 - NATUS MEDICAL INC (0000878526) (Issuer)

    7/21/22 5:20:45 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial Officer

    SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc

    9/18/23 9:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Novanta Set to Join S&P MidCap 400; Six Flags Entertainment to Join S&P SmallCap 600

    NEW YORK, July 21, 2022 /PRNewswire/ -- Novanta Inc. (NASD: NOVT) will replace Six Flags Entertainment Corp. (NYSE:SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical Inc. (NASD: NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 26, 2022 S&P MidCap 400 Addition Novanta NOVT Information Technology S&P MidCap 400

    7/21/22 6:36:00 PM ET
    $NOVT
    $NTUS
    $SIX
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

    MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue

    7/21/22 9:13:26 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    SEC Filings

    View All

    SEC Form 15-12G filed by Natus Medical Incorporated

    15-12G - NATUS MEDICAL INC (0000878526) (Filer)

    8/1/22 4:09:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Natus Medical Incorporated

    EFFECT - NATUS MEDICAL INC (0000878526) (Filer)

    7/25/22 12:15:44 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Natus Medical Incorporated

    EFFECT - NATUS MEDICAL INC (0000878526) (Filer)

    7/25/22 12:15:29 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Leadership Updates

    Live Leadership Updates

    View All

    Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial Officer

    SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc

    9/18/23 9:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical Announces Executive Transition

    Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earlier this year, the Board of Directors engaged a strategic consulting firm to assist it in developing a strategy to build upon Natus' market leading p

    12/17/21 4:01:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Financials

    Live finance-specific insights

    View All

    ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

    MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue

    7/21/22 9:13:26 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash

    Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app

    4/18/22 7:00:00 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th

    PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes

    4/1/22 4:10:00 PM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NTUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Natus Medical Incorporated (Amendment)

    SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)

    2/2/22 9:06:01 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Natus Medical Incorporated

    SC 13G - NATUS MEDICAL INC (0000878526) (Subject)

    1/19/22 7:51:36 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)

    2/10/21 11:28:21 AM ET
    $NTUS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care